Previous　studies　have　investigated　the　associations　between　the　two　polymorphisms　(prostate　stem　cell　antigen　(PSCA)　rs2294008　C/T　and　c-MYC　rs9642880　G/T)　and　bladder　cancer　(BC)　risk.　However,　the　results　are　inconsistent.　We　therefore　carried　out　a　meta-analysis　to　estimate　the　relationship　between　PSCA/c-MYC　polymorphisms　and　BC　risk.　We　searched　PubMed　up　to　November　2014　to　identify　potentially　eligible　literatures.　Odds　ratios　(ORs)　and　95%　confidence　intervals　(CIs)　were　used　to　estimate　the　strength　of　the　associations,　the　data　were　further　stratified　by　ethnicity.　Heterogeneity　was　evaluated　by　Q　test　and　I(2)　statistics.　Begg＇s　funnel　plot　and　Egger＇s　test　were　used　to　assess　the　publication　bias.　11　studies　from　9　articles　were　identified,　including　a　total　of　16,814　cancer　cases　and　52,868　case-free　controls.　We　found　a　significant　association　between　PSCA　rs2294008　polymorphism　and　BC　risk　(the　allele　contrast　model:　OR　=　1.14,　95%　CI　=　1.11-1.18;　homozygote　comparison:　OR　=　1.28,　95%　CI　=　1.20-1.37;　heterozygote　comparison:　OR　=　1.23,　95%　CI　=　1.17-1.30;　dominant　model:　OR　=　1.25,　95%　CI　=　1.19-1.31　and　recessive　model:　OR　=　1.13,　95%　CI　=　1.07-1.20).　Moreover,　a　significant　increased　risk　of　BC　was　confirmed　both　in　Caucasian　and　in　Asians.　For　c-MYC　rs9642880　polymorphism,　significant　increased　BC　risk　was　detected　under　the　following　genetic　models　(the　allele　contrast　model:　OR　=　1.20,　95%　CI　=　1.13-1.27;　homozygote　comparison:　OR　=　1.37,　95%　CI　=　1.21-1.55;　heterozygote　comparison:　OR　=　1.20,　95%　CI　=　1.09-1.32;　dominant　model:　OR　=　1.25,　95%　CI　=　1.14-1.37　and　recessive　model:　OR　=　1.26,　95%　CI　=　1.13-1.40).　Further　stratified　analysis　by　ethnicity　also　observed　the　same　results.　This　meta-analysis　suggested　that　PSCA　rs2294008　and　c-MYC　rs9642880　polymorphisms　may　increase　the　BC　risk.　Further　studies　are　needed　to　clarify　the　effects.